46996
document
Cost-effectiveness of cognitive-behavioral group therapy for dysfunctional fear of progression in cancer patients . Anxiety and fear are often associated with chronic conditions such as cancer . This paper targets the cost-effectiveness analysis of a cognitive-behavioral group therapy ( CBT ) in comparison to a client-centered , supportive-experiential group therapy ( SET ) in cancer patients with dysfunctional fear of progression . An incremental cost-effectiveness analysis was performed using data from a randomized controlled trial among cancer patients receiving inpatient rehabilitation . The means , 95 % confidence intervals [ 95 % CI ] , incremental cost-effectiveness graphic and acceptability curve were obtained from 1,000 bootstrap replications . A total of 174 patients were included in the economic evaluation . The estimated means [ 95 % CI ] of direct costs and reduction of fear of progression were < euro > 9,045.03 [ 6,359.07 ; 12,091.87 ] and 1.41 [ 0.93 ; 1.92 ] for patients in the SET and < euro > 6,682.78 [ 4,998.09 ; 8,440.95 ] and 1.44 [ 1.02 ; 1.09 ] for patients in the CBT . The incremental cost-effectiveness ratio [ 95 % CI ] amounts to minus < euro > 78,741.66 [ -154,987.20 ; 110,486.32 ] for an additional unit of effect . Given the acceptability curve , there is a 92.4 % chance that the CBT , compared with the SET , is cost-effective without the need of additional costs to payers . Our main result is the superior cost-effectiveness of the cognitive-behavioral intervention program in comparison to the non-directive encounter group for our sample of cancer patients with high levels of anxiety .
46997
Intervention_Psychological
cognitive-behavioral group therapy
46998
Intervention_Psychological
cognitive-behavioral group therapy ( CBT )
46999
Intervention_Psychological
client-centered , supportive-experiential group therapy ( SET )
47000
Intervention_Psychological
CBT
47001
Intervention_Educational
cognitive-behavioral intervention
47002
Outcome_Other
Cost-effectiveness
47003
Outcome_Mental
Anxiety
47004
Outcome_Mental
fear
47005
Outcome_Other
cost-effectiveness analysis
47006
Outcome_Other
cost-effectiveness analysis
47007
Outcome_Other
incremental cost-effectiveness graphic and acceptability curve
47008
Outcome_Other
direct costs
47009
Outcome_Mental
reduction of fear of progression
47010
Outcome_Other
incremental cost-effectiveness ratio
47011
Outcome_Other
acceptability curve
47012
Outcome_Other
cost-effective
47013
Outcome_Other
cost-effectiveness
47014
Outcome_Mental
anxiety